Epigenetics: Mechanisms, potential roles, and therapeutic strategies in cancer progression

被引:6
作者
Wang, Dong [1 ]
Zhang, Yan [1 ]
Li, Qingbo [1 ]
Li, Yu [1 ]
Li, Wen [1 ]
Zhang, Ao [1 ]
Xu, Jingxuan [1 ]
Meng, Jingyan [2 ]
Tang, Lin [2 ]
Lyu, Shuhua [3 ]
机构
[1] Tianjin Univ Tradit Chinese Med, Grad Sch, Tianjin 301617, Peoples R China
[2] Tianjin Univ Tradit Chinese Med, Coll Tradit Chinese Med, Tianjin 301617, Peoples R China
[3] Tianjin Union Med Ctr, Dept Pathol, Tianjin 300121, Peoples R China
基金
中国国家自然科学基金;
关键词
Cancer; Epigenetics; Gene expression; Heterogeneity; Tumor microenvironment; ACUTE MYELOID-LEUKEMIA; LONG NONCODING RNAS; STEM-LIKE CELLS; BREAST-CANCER; OVARIAN-CANCER; TUMOR; AZACITIDINE; FIBROBLASTS; SUPPRESSOR; EZH2;
D O I
10.1016/j.gendis.2023.04.040
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Mutations or abnormal expression of oncogenes and tumor suppressor genes are known to cause cancer. Recent studies have shown that epigenetic modifications are key drivers of cancer development and progression. Nevertheless, the mechanistic role of epigenetic dysregulation in the tumor microenvironment is not fully understood. Here, we reviewed the role of epigenetic modifications of cancer cells and non-cancer cells in the tumor microenvironment and recent research advances in cancer epigenetic drugs. In addition, we discussed the great potential of epigenetic combination therapies in the clinical treatment of cancer. However, there are still some challenges in the field of cancer epigenetics, such as epigenetic tumor heterogeneity, epigenetic drug heterogeneity, and crosstalk between epigenetics, proteomics, metabolomics, and other omics, which may be the focus and difficulty of cancer treatment in the future. In conclusion, epigenetic modifications in the tumor microenvironment are essential for future epigenetic drug development and the comprehensive treatment of cancer. Epigenetic combination therapy may be a novel strategy for the future clinical treatment of cancer. (c) 2023 The Authors. Publishing services by Elsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an open access article under the CC BY license (http://creativecommons.org/ licenses/by/4.0/).
引用
收藏
页数:15
相关论文
共 103 条
[91]   Oncogenic long noncoding RNA landscape in breast cancer [J].
Xu, Shouping ;
Kong, Dejia ;
Chen, Qianlin ;
Ping, Yanyan ;
Pang, Da .
MOLECULAR CANCER, 2017, 16
[92]   Non-coding RNA in cancer [J].
Yan, Huiwen ;
Bu, Pengcheng .
NON-CODING GENOME, 2021, 65 (04) :625-639
[93]   PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1/BRCA1 DNA damage repair complex in prostate cancer cells [J].
Yin, Linglong ;
Liu, Youhong ;
Peng, Yuchong ;
Peng, Yongbo ;
Yu, Xiaohui ;
Gao, Yingxue ;
Yuan, Bowen ;
Zhu, Qianling ;
Cao, Tuoyu ;
He, Leye ;
Gong, Zhicheng ;
Sun, Lunquan ;
Fan, Xuegong ;
Li, Xiong .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2018, 37
[94]   PPARα Inhibition Overcomes Tumor-Derived Exosomal Lipid-Induced Dendritic Cell Dysfunction [J].
Yin, Xiaozhe ;
Zeng, Wenfeng ;
Wu, Bowen ;
Wang, Luoyang ;
Wang, Zihao ;
Tian, Hongjian ;
Wang, Luyao ;
Jiang, Yunhan ;
Clay, Ryan ;
Wei, Xiuli ;
Qin, Yan ;
Zhang, Fayun ;
Zhang, Chunling ;
Jin, Lingtao ;
Liang, Wei .
CELL REPORTS, 2020, 33 (03)
[95]   Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability [J].
Yu, Ganjun ;
Wang, Wenying ;
He, Xiaobo ;
Xu, Jia ;
Xu, Rongrong ;
Wan, Tao ;
Wu, Yanfeng .
FRONTIERS IN ONCOLOGY, 2022, 12
[96]   Development of a versatile DNMT and HDAC inhibitor C02S modulating multiple cancer hallmarks for breast cancer therapy [J].
Yuan, Zigao ;
Chen, Shaopeng ;
Gao, Chunmei ;
Dai, Qiuzi ;
Zhang, Cunlong ;
Sun, Qinsheng ;
Lin, Jin-Shun ;
Guo, Chun ;
Chen, Yuzong ;
Jiang, Yuyang .
BIOORGANIC CHEMISTRY, 2019, 87 :200-208
[97]   Histone Modifications and their Role in Epigenetics of Cancer [J].
Zaib, Sumera ;
Rana, Nehal ;
Khan, Imtiaz .
CURRENT MEDICINAL CHEMISTRY, 2022, 29 (14) :2399-2411
[98]   Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer [J].
Zhang, Tiancheng ;
Li, Xiang ;
He, Yani ;
Wang, Yaohui ;
Shen, Jiajia ;
Wang, Shoulin ;
You, Qiang ;
Zhai, Jing ;
Shen, Lizong .
GASTRIC CANCER, 2022, 25 (02) :346-359
[99]   HDAC6 expression is correlated with better survival in breast cancer [J].
Zhang, ZH ;
Yamashita, H ;
Toyama, T ;
Sugiura, H ;
Omoto, Y ;
Ando, Y ;
Mita, K ;
Hamaguchi, M ;
Hayashi, S ;
Iwase, H .
CLINICAL CANCER RESEARCH, 2004, 10 (20) :6962-6968
[100]   Epigenetic Targets and their Inhibitors in Cancer Therapy [J].
Zhao, Le ;
Duan, Yong-Tao ;
Lu, Ping ;
Zhang, Zhi-Juan ;
Zheng, Xiao-Ke ;
Wang, Jun-Lei ;
Feng, Wei-Sheng .
CURRENT TOPICS IN MEDICINAL CHEMISTRY, 2018, 18 (28) :2395-2419